Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Microbiome Cancer Immunotherapy Project Aims To Improve Oncology Drugs

XTALKS VITALS NEWS

Microbiome

While the immunotherapies will be aimed at improving the efficacy of currently-available oncology drugs, they could also act as monotherapeutics for cancer treatment.

Tweetables from this article:

Tweet: New class of microbiome-derived cancer immunotherapy agents to be used in combination with checkpoint inhibitor drugs http://ctt.ec/5a6gw+New class of microbiome-derived cancer immunotherapy agents to be used in combination with checkpoint inhibitor drugs.

Tweet: Vedanta secured $50 million in funding to develop microbiome therapeutics to treat infectious and autoimmune diseases http://ctt.ec/5md0J+Vedanta secured $50 million in funding to develop microbiome therapeutics to treat infectious and autoimmune diseases.

Share this!

August 15, 2016 | by Sarah Massey, M.Sc.

A new class of microbiome-derived cancer immunotherapy agents to be used in combination with checkpoint inhibitor drugs, are set to be developed by Vedanta Biosciences and NYU Langone Medical Center. While the immunotherapies will be aimed at improving the efficacy of currently-available oncology drugs, they could also act as monotherapeutics for cancer treatment.

Earlier this year, Vedanta secured $50 million in funding to develop microbiome therapeutics to treat infectious and autoimmune diseases. The company – founded by PureTech Health – hopes to get these drugs into the clinic in 2017.

“Dr. Weber is a pioneer in translational research, particularly in immunotherapy and the development of checkpoint inhibitors,” said CSO of Vedanta, Bruce Roberts, commenting on the leader of the project. “We look forward to working with Dr. Weber to expand Vedanta’s portfolio of immune activating microbial cocktails for use in standalone immunotherapy and in combination with checkpoint inhibitors.”



Verdanta’s interest in oncology comes at a turbulent time in microbiome therapeutics research. A Phase II clinical trial of an oral microbiome drug, led by Seres Therapeutics, failed to meet its endpoint of reducing the risk of Clostridium difficile infection.

The company’s collaboration with NYU aims to investigate the mechanisms by which gut bacteria impact checkpoint inhibitor drug efficacy as a cancer therapy. Vedanta researchers believe that human gut bacteria could be harnessed to develop effective immunotherapies.

“Checkpoint inhibitors are a major advance in cancer therapy, but many patients do not respond to therapy, and some patients who respond will eventually relapse,” said Dr. Jeffrey Weber, who is the deputy director of the Laura and Isaac Perlmutter Cancer Center at NYU Langone. “Recent data suggest an important role for the microbiome in the anti-tumor activity of immunotherapy, and our other studies of the microbiome will offer interesting new clinical insights into how and why these treatments work.”


Keywords: Microbiome, Immunotherapy, Oncology


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Small Molecule May Disrupt Biofilm Formation on Implantable Medical Devices

March 28, 2017 - Researchers at Trinity College Dublin in Ireland have identified a small molecule capable of preventing bacterial biofilms from growing on medical implants.

Featured In: Medical Device News


FDA Approves PD-L1 Immunotherapy Developed by Pfizer and Merck KGaA

March 27, 2017 - Pfizer and Merck KGaA’s PD-L1 inhibitor, Bavencio (avelumab), has become the first immunotherapy to be approved by the US Food and Drug Administration (FDA) to treat a rare form of skin cancer, known as metastatic Merkel cell carcinoma (MCC).

Featured In: Biotech News


New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

Strategies for Deploying Innovative Solutions for Perimeter Security


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.